Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.

Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.

Epic Sciences spoke to Medtech Insight to discuss the development of its DefineMBC test for metastatic breast cancer.

Cooper expects the addition of Cook’s products and staff will allow it to reach more patients, especially in the fast-growing Asia-Pacific fertility market.